Biogen CEO Michel Vounatsos told CNBC that the list price of $56,000 per year for the company's FDA-approved Alzheimer's disease drug aducanumab is "fair."| CNBC
Trump on Tuesday said his administration will be announcing a "major" tariff on pharmaceuticals "very shortly."| CNBC
AstraZeneca's CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing market with new free offering.| CNBC
Epic Systems, the electronic health records giant, cut off its data supply to Particle Health, claiming the startup was using information in unauthorized ways.| CNBC
Change Healthcare confirmed that ransomware group Blackcat is behind the ongoing cybersecurity attack that's been impacting its systems since last week.| CNBC
